The project is using CRISPR/Cas9 technology in adaptive NK cells to create a new cell therapy product.
“We aim to create a powerful cell therapy product by reworking three key elements: enhancing cytotoxic potency, expanding targetable space and extending cell persistence”, Lamberto says on LinkedIn.
The project builds upon the development of the ADAPT-NK cell product that is a cell therapy product developed in Karl-Johan Malmberg’s group soon to be tested in clinical trials.